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Abstract
Introduction Disturbances in microcirculatory homeostasis
have been hypothesized to play a key role in the pathophysiology
of multiple organ dysfunction syndrome and vasopressor-
associated ischemic skin lesions. The effects of a
supplementary arginine vasopressin (AVP) infusion on
microcirculation in vasodilatory shock and postoperative
multiple organ dysfunction syndrome are unknown.
Method Included in the study were 18 patients who had
undergone cardiac or major surgery and had a mean arterial
blood pressure below 65 mmHg, despite infusion of more than
0.5  µg/kg per min norepinephrine. Patients were randomly
assigned to receive a combined infusion of AVP/norepinephrine
or norepinephrine alone. Demographic and clinical data were
recorded at study entry and after 1 hour. A laser Doppler
flowmeter was used to measure the cutaneous microcirculatory
response at randomization and after 1 hour. Reactive
hyperaemia and oscillatory changes in the Doppler signal were
measured during the 3 minutes before and after a 5-minute
period of forearm ischaemia.
Results Patients receiving AVP/norepinephrine had a
significantly higher mean arterial pressure (P  = 0.047) and
higher milrinone requirements (P = 0.025) than did the patients
who received norepinephrine only at baseline. Mean arterial
blood pressure significantly increased (P  < 0.001) and
norepinephrine requirements significantly decreased (P  <
0.001) in the AVP/norepinephrine group. Patients in the AVP/
norepinephrine group exhibited a significantly higher oscillation
frequency of the Doppler signal before ischaemia and during
reperfusion at randomization. During the study period, there
were no differences in either cutaneous reactive hyperaemia or
the oscillatory pattern of vascular tone between groups.
Conclusion Supplementary AVP infusion in patients with
advanced vasodilatory shock and severe postoperative multiple
organ dysfunction syndrome did not compromise cutaneous
reactive hyperaemia and flowmotion when compared with
norepinephrine infusion alone.
Introduction
Impaired microcirculatory blood flow has been identified as a
key component in the pathophysiology of multiple organ dys-
function syndrome after surgery [1] and in sepsis [2]. The pre-
cise mechanisms involved remain unclear but include complex
interactions between various factors: increased heterogeneity
of capillary blood flow; reduced erythrocyte deformability;
endothelial cell dysfunction with increased permeability and
apoptosis; altered vasomotor tone; increased numbers of acti-
vated neutrophils with more neutrophil-endothelial interac-
tions; and activation of the clotting cascade with formation of
microthrombi [3]. De Backer and colleagues [2] identified
impaired capillary perfusion, assessed by orthogonal polariza-
tion spectrophotometry, as an independent predictor of mor-
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tality in severe sepsis. Similarly, Sakr and colleagues [4]
observed that patients who died from persistent septic multi-
ple organ dysfunction had markedly impaired microcirculatory
perfusion over time compared with surviving patients.
Although macrocirculatory parameters such as mean arterial
blood pressure (MAP) and cardiac output are unreliable for
predicting microcirculatory homeostasis, there is strong evi-
dence that a certain perfusion pressure – probably a MAP
above 65 mmHg if it is combined with adequate cardiac out-
put – is a prerequisite for adequate microcirculatory blood flow
[5-7]. Although vasopressor infusion alone is undoubtedly det-
rimental to microcirculatory blood flow, it is currently recom-
mended that fluid resuscitation and infusion of inotropic
agents to achieve adequate cardiac output be combined with
vasopressor therapy in order to realize a reasonable tissue per-
fusion pressure [5].
However, in a small group of patients with cardiocirculatory
failure, recommended standard therapy alone is not sufficient
to attain a MAP necessary to maintain perfusion of an altered
microcirculation.
Table 1
Changes in haemodynamic variables, acid-base status, reactive hyperaemia, and vasomotion
Parameters Group Baseline 1 hour P
MAP (mmHg) AVP/NE* 64 ± 5 81 ± 12 0.047†
NE 64 ± 9 66 ± 13
CI (l/min per m2) AVP/NE 4.1 ± 1.2 3.8 ± 1.1 0.152
NE 3.5 ± 0.9 3.5 ± 0.8
DO2I (ml/min/m2) AVP/NE 571 ± 140 526 ± 130 0.151
NE 482 ± 111 493 ± 119
VO2I (mL/min/m2) AVP/NE 155 ± 39 157 ± 35 0.077
NE 131 ± 35 137 ± 41
SvO2 (%) AVP/NE 72 ± 6 66 ± 13 0.583
NE 71 ± 9 70 ± 10
NE requirements (µg/kg per min) AVP/NE* 0.75 ± 0.31 0.51 ± 0.19 0.36
NE 0.65 ± 0.23 0.76 ± 0.18
Milrinone requirements (µg/kg per min) AVP/NE 0.44 ± 0.15 0.44 ± 0.16 0.025†
NE 0.31 ± 0.2 0.29 ± 0.19
pH AVP/NE 7.30 ± 0.12 7.30 ± 0.12 0.355
NE 7.33 ± 0.1 7.32 ± 0.08
Lactate (mmol/l) AVP/NE 5.9 ± 6.7 6.6 ± 6.3 0.548
NE 7.6 ± 6.1 7.5 ± 5.6
AUC pre-ischaemic AVP/NE 21.2 ± 9.4 16.7 ± 7.7 0.089
NE 15.3 ± 10.2 15.3 ± 9.0
Magnitude of RH (%) AVP/NE 64 ± 57.2 70 ± 47.5 0.56
NE 49.4 ± 24.8 48.7 ± 41.7
ODS pre-ischaemic (oscillations/min) AVP/NE‡ 15.73 ± 5.15 14.38 ± 7.31 0.055§
NE 7.49 ± 3.2 10.7 ± 3.81
ODS reperfusion (oscillations/min) AVP/NE‡ 14.38 ± 4.85 13.78 ± 9.17 0.601§
NE 8.99 ± 3.92 10.7 ± 5.7
Data are expressed as mean values ± standard deviation. AUC, area under the curve; AVP, arginine vasopressin; CI, cardiac index; DO2I, systemic 
oxygen transport index; MAP, mean arterial pressure; NE, norepinephrine; ODS, oscillation of the Doppler signal; RH, reactive hyperaemia; SvO2, 
mixed venous oxygen saturation; VO2I, systemic oxygen consumption index. *significant difference over time; †, significant difference between 
groups; ‡, significant difference at baseline between groups; §, corrected for baseline differences.Available online http://ccforum.com/content/10/2/R40
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It has been reported that supplementary infusion of arginine
vasopressin (AVP) can reliably increase MAP to above 65
mmHg, even in patients with advanced cardiovascular failure
who are resistant to standard treatment [8-10]. However,
when AVP was continuously infused in healthy animals it
resulted in severe disturbances in capillary blood flow and tis-
sue oxygenation [11]. The effects of a supplementary AVP
infusion on microcirculation in humans with severe cardiovas-
cular failure are unknown. Exacerbation of microvascular fail-
ure by a therapeutic intervention such as vasopressor therapy
would be detrimental to cell oxygenation, organ regeneration
and, ultimately, patient survival. Our study group reported a
30.2% incidence of ischaemic skin lesions in patients with
advanced vasodilatory shock during supplementary AVP infu-
sion [12].
This clinical study was conducted to evaluate prospectively
the cutaneous microcirculatory response to a combined infu-
sion of AVP and norepinephrine when compared with infusion
of norepinephrine alone, using laser Doppler flowmetry in
patients with advanced vasodilatory shock and severe postop-
erative multiple organ dysfunction syndrome (Table 1).
Materials and methods
The study protocol was approved by the institutional review
board and the ethical committee of the Innsbruck Medical Uni-
versity, Innsbruck, Austria. Written informed consent was
obtained from each patient's next of before randomization.
We prospectively enrolled 18 critically ill patients suffering
from severe multiple organ dysfunction syndrome following
cardiac or major surgery, with a MAP below 65 mmHg despite
adequate volume resuscitation, and norepinephrine require-
ments in excess of 0.5 µg/kg per minute. Patients with periph-
eral arterial vascular occlusive disease or insulin-dependent
diabetes mellitus were excluded. All patients were subjected
to invasive monitoring including central venous, arterial and
pulmonary artery catheter. Fluid resuscitation was performed
using colloid solutions until the stroke volume index could not
be increased further by volume loading. The corresponding
pulmonary capillary wedge pressure was used as a therapeu-
tic target for further fluid resuscitation. If stroke volume index
remained below 25 ml/min per m2, cardiac index remained
below 2 l/min per m2, or mixed venous saturation remained
below 65%, then a continuous infusion of milrinone was
started at doses ranging from 0.3 to 0.7 µg/kg per minute. All
patients were mechanically ventilated and received analgesic
and sedative drugs (for instance, continuous infusion of sufen-
tanil and midazolam). There was no difference in the dosage of
analgesic and sedative drugs between groups. No patient was
paralyzed at the time of study measurements.
Upon inclusion in the study, patients were randomly assigned
to an AVP/norepinephrine or a norepinephrine-only group,
guided by a random number generating computer program.
The study was not blinded. In patients in the AVP/norepine-
phrine group, supplementary AVP (Pitressin®; Pfizer, Karl-
sruhe, Germany) was infused at a continuous rate of 4 IU/hour;
no bolus injections were administered. Norepinephrine infu-
sion was adjusted to maintain MAP above 65 mmHg. In
patients in the norepinephrine group, a MAP above 65 mmHg
was achieved by adjusting the norepinephrine dosage.
Age, sex, past medical history (arterial hypertension, conges-
tive heart failure, coronary heart disease, chronic pulmonary
disease, chronic renal disease, non-insulin-dependent diabe-
tes mellitus) and intensive care unit mortality were recorded in
all patients. A modified Goris multiple organ dysfunction syn-
drome score [13] was calculated from the worst clinical data
recorded before study entry; MAP, cardiac index, systemic
oxygen transport and consumption variables, norepinephrine
and milrinone requirements, as well as pH and arterial lactate
concentrations were documented immediately before and 1
hour after randomization.
Cutaneous microcirulatory measurements were performed
using a laser Doppler flowmeter (Periflux 4001; Perimed, Jär-
fälla, Sweden). A fiberoptic guidewire (PF407; Perimed) con-
ducts laser light with a wavelength of 770–790 nm to tissue
(catchment volume about 1 mm3) and carries back-scattered
light to a photodetector. Calibration of the photodetector was
performed using the manufacturer's calibration kit. The surface
of a white compact synthetic material was used to set the zero
value for arbitrary perfusion units, whereas the second value of
the calibration curve (perfusion units = 250) was derived by
measurement in a motility standard fluid (Perimed). The elec-
trode was placed on the volar aspect of the forearm and held
in place by a thin transparent silicon rubber patch. This patch
remained in the same place during the study period in order to
reduce short-term intra-individual variation in laser Doppler
flowmetry, which was reported to be 25.4%. Inter-individual
variation was observed to be 36% [14]. Using this setting,
laser Doppler flowmetry has been shown to be an suitable
technique for evaluating both reactive hyperaemia [15] and
oscillatory changes in vascular tone [16].
Baseline measurements included the area under the curve
(AUC) of the Doppler signal (given in perfusion units) and
oscillatory changes (oscillations/min) of the Doppler signal
over 3 minutes (pre-ischaemic). Afterward, forearm ischaemia
was produced by wrapping a sphygomanometer cuff around
the arm over the brachial artery and inflating it to 300 mmHg
for 5 minutes. During the first 3 minutes of reperfusion, the
AUC of the Doppler signal as well as oscillatory changes in the
Doppler signal were measured (reperfusion). The relative mag-
nitude of reactive hyperaemia, as a percentage, was deter-
mined using the formula 100 × (AUCreperfusion  - AUCpre-
ischaemic)/AUCpre-ischaemic (Figure 1), in order to compensate for
individual differences in forearm skin vascularization. TheseCritical Care    Vol 10 No 2    Luckner et al.
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sets of measurements were performed in all patients immedi-
ately before and 1 hour after randomization.
For flowmotion analysis, the Doppler signal tracing was
divided into nine blocks of 20 seconds each before induction
of ischaemia and during reperfusion measurements (Figure 1).
Fast Fourier transformation analysis was performed for single
blocks to obtain a quantitative description of the main oscilla-
tory frequency component. After computing a power spectrum
for each block, the medians were averaged to give the final
power spectrum for pre-ischaemic and reperfusion oscilla-
tions. Frequencies corresponding to heart rate or mechanical
ventilation were discarded. Mean values of oscillation were
used for statistical comparisons.
Statistical analysis
The primary objective of the study was to evaluate differences
in the AUC of the Doppler signal and the reactive hyperaemic
response to forearm ischaemia between AVP/norepinephrine
and norepinephrine groups. The secondary study objective
was to evaluate differences in the oscillation frequency of the
Doppler signal between groups.
Demographic and clinical data were compared using Stu-
dent's t test or χ2 tests, as appropriate (SPSS® 11.0 for Win-
dows; SPSS Inc., Chicago, IL, USA). To evaluate differences
in haemodynamic, acid-base and microcirculatory variables
between groups at baseline and over time, an unpaired Stu-
dent's t test was performed. For variables that did not fulfil the
normality assumption (AUC pre-ischaemic, magnitude of reac-
tive hyperaemia, oscillation of the Doppler signal before
ischaemia and during reperfusion), nonparametric tests
(Mann-Whitney U rank sum tests) were applied. For detection
of changes in single variables between the two measurements
in each of the study groups, a paired Student's t test was used.
The main effects between groups and within repeated meas-
urements were considered to indicate statistical significance if
the P value was below 0.05. All data are expressed as mean
values ± standard deviation, unless indicated otherwise.
Results
Cardiovascular function could not be stabilized adequately by
incremental dosages of norepinephrine in one patient ran-
domly assigned to the norepinephrine group, but MAP could
be restored with supplementary AVP infusion. This patient was
therefore switched to the AVP/norepinephrine group for statis-
tical evaluation.
Of all study patients, 55% (10 out of 18) were admitted to the
intensive care unit after heart surgery. The other eight patients
were admitted because of severe systemic inflammatory
response syndrome or sepsis after major abdominal surgery (n
= 6) or noncardiac surgical thoracic surgery (n = 2). The time
between admission to the intensive care unit and study entry
was between 24 and 36 hours in all patients.
Between AVP/norepinephrine (n = 10) and norepinephrine
patients (n = 8), there were no differences in age (70.5 ± 8.5
years versus 67 ± 7.1 years; P = 0.196), male sex (60% ver-
sus 62.5%; P = 1), pre-existing morbidity (P = 0.784), multiple
organ dysfunction syndrome score (12.3 ± 1.1 versus 12.2 ±
0.4; P = 0.84), and intensive care unit mortality (80 versus
87.5%; P = 1).
Table 1 presents macrocirculatory, acid-base, and laser Dop-
pler flowmetry derived variables in the AVP/norepinephrine
and norepinephrine groups. Patients receiving AVP/norepine-
phrine had significantly higher MAP and milrinone require-
ments than did those in the norepinephrine group. During the
observation period, MAP increased significantly (P < 0.001)
and norepinephrine requirements significantly decreased (P <
0.001) in the AVP/norepinephrine group. There were no fur-
ther differences in haemodynamic or acid-base variables
between groups or over time.
No differences in the pre-ischaemic AUC of the Doppler signal
and in the magnitude of reactive hyperaemia occurred
between groups before and 1 hour after randomization.
Patients receiving AVP/norepinephrine had a higher oscillation
frequency of the Doppler signal before ischaemia and during
reperfusion at study inclusion than did patients receiving nore-
pinephrine alone. One hour after study drug infusion there was
no difference in the oscillation frequency before ischaemia and
during reperfusion between groups when adjusted for base-
line differences.
Discussion
As described previously [10,11], supplementary AVP infusion
was beneficial in that it improved MAP and allowed norepine-
phrine dosage to be reduced compared with norepinephrine
infusion alone. AVP therapy neither reduced the pre-ischaemic
AUC of the Doppler signal nor reduced the magnitude of the
reactive hyperaemic response at up to five minutes of forearm
ischaemia. Additionally, there was no difference in the
response of the oscillation frequency detected by laser Dop-
pler flowmetry.
Reactive hyperaemia is the transient increase in organ blood
flow that occurs after ischaemia. In general, the ability of an
organ to exhibit reactive hyperemia reflects the autoregulative
capacity of its microcirculation [1]. Representing the propor-
tion of recruitable capillaries, arterioles, and small arteries,
reactive hyperaemia was found to be significantly attenuated
in patients with shock [1,17,18]. In this study, the combined
infusion of AVP and norepinephrine did not change the pre-
ischaemic AUC of the Doppler signal and the magnitude of
reactive hyperaemia when compared with patients receiving
norepinephrine infusion alone. Thus, even though AVP signifi-
cantly increased MAP, its strong vasoconstrictive effects
clearly did not further compromise autoregulation of the cuta-
neous microcirculation in severe postoperative multiple organAvailable online http://ccforum.com/content/10/2/R40
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dysfunction syndrome. Nonetheless, it cannot be excluded
that a higher MAP, as seen in the AVP/norepinephrine group
after 1 hour, could have concealed a potentially deleterious
effect of AVP on the reactive hyperaemic response. An
unchanged AUC of the laser Doppler signal before induction
of forearm ischaemia indicates that AVP did not significantly
reduce blood flow in the skin tissue volume examined.
Vasomotion is the oscillation of vascular tone that is generated
from within the vascular wall; it is not a consequence of heart
beats, respiration, or neuronal input [16]. Initiation of vasomo-
tion can be observed during hypoxia, tissue hypoperfusion,
acidosis, and during AVP infusion in the skin of healthy ham-
sters [11]. Because blood vessels with an oscillating diameter
have higher conductance than do vessels with a constant
diameter of the same average width [19], it was suggested
that vasomotion might reflect a rescue mechanism in condi-
tions of tissue hypoxia in order to ensure adequate tissue oxy-
genation [16]. In this study population with advanced
cardiovascular failure and severe postoperative multiple organ
dysfunction syndrome, combined infusion of AVP and nore-
pinephrine did not increase oscillation frequency of the Dop-
pler signal when compared with norepinephrine infusion alone.
At least in these patients, this finding may indicate that AVP/
norepinephrine does not result in further deterioration in micro-
circulatory oxygen supply in skin.
These findings are in striking contrast to the results of a phys-
iologic animal experiment, in whihc the effects of AVP on the
microcirculation were analyzed in the skinfold of healthy ham-
sters [11]. In that model, doses of AVP similar to those used
in clinical practice (4 IU/hour) resulted not only in significant
reductions in skin blood flow and oxygenation but also in an
increase in vasomotion frequency. Aside from species
dependent variations, differences between physiological and
pathophysiological states appear to be important determi-
nants of the effects of AVP on cutaneous microcirculatory
flow. Although AVP induces substantial vasoconstriction in
normally contracted arterioles in healthy animals, the effects of
AVP in an excessively vasodilated microcirculation [20] with
decreased susceptibility to AVP [21-23] appear to be signifi-
cantly different.
Thus far only two case reports have been reported that
describe the microcirculatory response to AVP in patients with
advanced shock states. Similar to our data, no further deterio-
ration in microcirculatory flow in the sublingual tissue, as
assessed by orthogonal polarization spectrophotometry, was
detected during supplementary AVP infusion by Dubois and
colleagues [24]. Interestingly, in this patient administration of
AVP actually appeared to improve microcirculatory flow
because of an increase in the proportion of perfused capillar-
ies [24]. Recently, Boerma and colleagues [25] used the same
technique in a patient with terminal septic shock receiving a
bolus injection of terlipressin. In contrast to the first case
report and our findings, a dramatic decrease in small vessel
numbers and, ultimately, a complete standstill in sublingual
capillary flow occurred.
In their patient, Boerma and colleagues [25] further observed
clinically evident hypoperfusion of the distal extremities, a
decreased peripheral perfusion index, as well as a substantial
increase in the central-to-toe temperature difference (from 1.7
to 13.4°C) after terlipressin injection. Similarly, our study
group reported a 30.2% incidence of ischaemic skin lesions in
patients with advanced vasodilatory shock during supplemen-
tary AVP infusion [12]. However, in a prospective, controlled
study, ischaemic skin lesions occurred at a comparable rate in
severe shock patients with or without AVP infusion, indicating
that ischaemic lesions of the skin rather reflect severity of the
Figure 1
Principles of measurement of reactive hyperaemia and flowmotion  using laser Doppler flowmetry Principles of measurement of reactive hyperaemia and flowmotion 
using laser Doppler flowmetry. (a) Original Doppler tracing in a patient 
over a time period of 11 minutes (3 minutes pre-ischaemic, 5 minutes 
ischaemia, 3 minutes reperfusion time). The area under the curve 
(AUC) was calculated for each time interval. 1 = AUC pre-ischemic; 2 
= AUC during ischaemia; 3 = AUC during reactive hyperaemia; 1 + 3 = 
AUC during reperfusion. (b) Twenty seconds of an original Doppler 
tracing with superimposed fast Fourier transformation. Computed anal-
ysis of the original plot reveals two oscillations with different frequen-
cies representing heart rate and flowmotion.Critical Care    Vol 10 No 2    Luckner et al.
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underlying microcirculatory failure than direct adverse side
effects of AVP infusion [8]. Taking these limited data together,
it seems that several factors (for example, dose, the vaso-
pressin analogue used, circulating blood volume and cardiac
output, severity of illness and microcirculatory dysfunction) as
well as genetic factors determine the microcirculatory
response to AVP-induced vasoconstriction in advanced cardi-
ovascular failure.
When interpreting the results of this study, important limita-
tions must be considered. First, because measurements taken
in the present study can only be interpreted as a response of
the skin vessels to AVP, these results may not be extrapolated
to other vascular beds. However, in contrast to most 'internal'
organs, vasoconstriction in skin is mediated almost exclusively
by receptors [26]; therefore, one could assume that the vaso-
constrictor response to any vasopressor agent would be most
pronounced in skin. Second, using laser Doppler flowmetry,
heterogeneity in microcirculatory blood flow, a consistent find-
ing in both endotoxaemic animal models [27,28] and human
studies [2,4], cannot be assessed. Therefore, unchanged
microcirculatory parameters during supplementary AVP infu-
sion, as indicated by laser Doppler flowmetry in this study pop-
ulation, does not exclude altered heterogeneity in
microcirculatory flow. Third, although no data exist on the
effects of milrinone and vasomotion, it cannot be ruled out that
the significantly higher milrinone dosages in the AVP/nore-
pinephrine groups mitigated a decrease in reactive hyperae-
mia and amplification of vasomotion. Finally, it is conceivable
that if measurements had been repeated 12 or 24 hours after
randomization, the microcirculatory response might have been
different from that reflected by measurements taken 1 hour
after randomization. Nonetheless, relevant changes in reactive
hyperaemia and arteriolar vasomotion are known to occur
within very short periods of time [29].
Conclusion
Supplementary AVP infusion in patients with advanced
vasodilatory shock and severe postoperative multiple organ
dysfunction syndrome did not compromise cutaneous reactive
hyperaemia and flowmotion when compared with norepine-
phrine infusion alone.
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